Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melpida intrathecal gene therapy for hereditary spastic paraplegia type 50
2025-522603-15-00Phase 2Authorised
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MELPIDA in Hereditary spastic paraplegia type 50 (SPG50), sponsored by Papa Giovanni XXIII Hospital. Primary endpoint: Change in total percent score of the eight Major Motor Milestones derived from the Gross Motor Function Measure (GMFM)-88. Planned start Sep 2026; status: authorised.
02
Drugs
MELPIDA
03
Conditions
Hereditary spastic paraplegia type 50 (SPG50)
Beyond the preview
Go deeper on 2025-522603-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522603-15-00.